Inhibikase Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Inhibikase Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?
Investors are testing whether Inhibikase Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Inhibikase Therapeutics, Inc. (IKT) Q1 2023 Earnings Call Transcript
Investors are testing whether Inhibikase Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Inhibikase Therapeutics, Inc. (IKT) Q4 2022 Earnings Call Transcript
Investors are testing whether Inhibikase Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q3 2022 Earnings Call Transcript
Investors are testing whether Inhibikase Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest IKT filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Inhibikase Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →